Table 1.
Characteristics of the patients without and with persistent peritonitis at the time of ICU admission for initial septic surgery
| Without persistent peritonitis | Persistent peritonitis | P | |
|---|---|---|---|
| n = 122 | n = 98 | ||
| Male gender, n (%) | 59 (48) | 58 (59) | 0.10 |
| Age, mean ± SD | 62 ± 18 | 62 ± 14 | 0.99 |
| Comorbidities | |||
| Cancer, n (%) | 51 (42) | 35 (36) | 0.35 |
| Diabetes, n (%) | 21 (17) | 10 (10) | 0.17 |
| Immunosuppression, n (%) | 17 (14) | 9 (9) | 0.29 |
| SAPS II score, mean ± SD | 49 ± 23 | 50 ± 16 | 0.85 |
| SOFA score, mean ± SD | 6.8 ± 3.9 | 8.2 ± 3.2 | 0.01 |
| Haemodynamic failure1, n (%) | 49 (40) | 59 (60) | 0.003 |
| Respiratory failure1, n (%) | 32 (26) | 36 (37) | 0.09 |
| Renal failure1, n (%) | 16 (13) | 22 (22) | 0.07 |
| Initial procedure leading to postoperative peritonitis | |||
| Emergency surgery, n (%) | 43 (35) | 47 (48) | 0.056 |
| Elective surgery, n (%) | 79 (65) | 51 (52) | - |
| Characteristics of the initial surgical procedure | |||
| Gastroduodenal surgery, n (%) | 32 (26) | 31 (32) | 0.37 |
| Colonic surgery, n (%) | 48 (39) | 45 (46) | 0.32 |
| Small bowel surgery, n (%) | 20 (16) | 19 (19) | 0.59 |
| Other type of surgery, n (%) | 22 (18) | 11 (11) | 0.18 |
| Aetiology of postoperative peritonitis | |||
| Bowel perforation, n (%) | 42 (34) | 48 (49) | 0.029 |
| Anastomotic leakage, n (%) | 42 (34) | 30 (30) | 0.54 |
| Purulent collection, n (%) | 17 (14) | 20 (20) | 0.21 |
| Other causes, n (%) | 21 (18) | 19 (19) | 0.72 |
| Primary site of infection above transverse mesocolon, n (%) | 30 (25) | 32 (33) | 0.18 |
| Colonic site of infection, n (%) | 40 (33) | 35 (36) | 0.65 |
| Small bowel site of infection, n (%) | 49 (41) | 32 (33) | 0.25 |
| Gastric site of infection, n (%) | 26 (21) | 25 (26) | 0.46 |
| Creation of ostomy, n (%) | 62 (53) | 54 (47) | 0.52 |
| Adequacy of empirical antibiotic therapy, n (%) | 79 (65) | 63 (64) | 0.94 |
| Use of combination of antibiotic therapy, n (%) | 88 (72) | 84 (86) | 0.02 |
| Use of carbapenems, n (%) | 24 (20) | 29 (30) | 0.09 |
| Use of piperacillin/tazobactam, n (%) | 84 (69) | 62 (63) | 0.38 |
| Use of vancomycin, n (%) | 43 (35) | 50 (51) | 0.02 |
| Use of aminoglycosides, n (%) | 50 (41) | 53 (54) | 0.053 |
| Use of empirical antifungal therapy, n (%) | 30 (25) | 43 (44) | 0.002 |
1Grade 3 or 4 of the SOFA score. SAPS II, simplified acute physiology score II; SOFA, sequential organ failure assessment.